Prostate Cancer

Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients. June 10, 2026

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL. June 10, 2026

Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI. June 10, 2026

Neoadjuvant Fc-Enhanced Anti-CTLA-4 Targets Tregs to Augment Androgen Deprivation in High-Risk Prostate Cancer: A Randomized Phase I Trial - Beyond the Abstract June 9, 2026

Progression-free Survival Following Primary Staging with [18F]PSMA-1007-PET/ceCT Versus Na[18F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial. June 9, 2026

Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report. June 9, 2026

Aglatimagene Besadenovec (CAN-2409) with Radiotherapy for Patients with Localised Prostate Cancer: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial - Beyond the Abstract June 8, 2026

Prospective Multicenter Randomized Controlled Trial of Stabilized Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results June 8, 2026

Enhancing foundation model transfer for prostate cancer detection with patch-level contrastive learning. June 8, 2026

Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer. June 8, 2026

177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil. June 10, 2026

Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements. June 10, 2026

Enhanced Telehealth in Prostate Cancer. June 10, 2026

Younger Age Is Associated With Early Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy. June 9, 2026

High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression. June 9, 2026

Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria. June 9, 2026

Artera Expands Its Validated Multimodal AI Platform to Metastatic Hormone‑Sensitive Prostate Cancer (mHSPC) June 8, 2026

Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases. June 8, 2026

Years of life lost from metastatic prostate cancer according to household income. June 8, 2026

A decision-oriented framework for genomic testing across the prostate cancer continuum. June 8, 2026

Page 1 of 1635